8 Mar 2025
Neuroendocrine tumors(NETs) are rare, relatively slow-growing cancers that originate in specialized cells called neuroendocrine cells. These tumors can develop in various organs throughout the body, such as the pancreas, lungs, or gastrointestinal tract. As the symptoms of NET may mimic other diseases, often leading to delayed diagnoses. Patients often face an uphill battle due to these complexities, underscoring the need for innovative treatment approaches.
CancerInformation.com.hk 癌症資訊網, in collaboration with ZERO Biotech, recently organized a groundbreaking medical seminar and patient sharing session focused on Neuroendocrine Tumors (NET) and the transformative potential of Peptide Receptor Radionuclide Therapy (PRRT) in treating this condition.
During the event, clinical oncologist Prof. Victor Lee first introduced Steve Jobs, co-founder of Apple, who passed away because of NET. Prof. Lee then shed light on the common symptoms, epidemiology and incidence of NET in Asia and the US. He continued to introduce the current standard of care hormonal therapy and targeted therapy for the disease. He further introduced the latest treatment strategies for NETs, in which PRRT showed high efficacy and low toxicity. PRRT is a targeted radiotherapy that delivers radiation directly to neuroendocrine tumor cells using a peptide that binds specifically to receptors on these cells. This precision treatment minimizes damage to surrounding healthy tissues, offering new hope to patients with advanced-stage NET.
A patient, who was grappling with Stage IV neuroendocrine tumors, shared his journey of seeking a remedy for his condition. He consulted different doctors and hospitals in Hong Kong and globally, before meeting Prof. Lee and under his care in Queen Mary Hospital. His story resonated with many attendees, showcasing the challenges faced by NET patients and the importance of innovative treatment approaches.
The encouraging story is the driving force for ZERO Biotech’s commitment in nuclear medicine as well as novel drug development with an aim to transform cancer patients’ lives. Through innovative research and a patient-centric approach, ZERO Biotech is at the forefront of revolutionizing cancer care and bringing new hope to individuals battling this challenging disease. We look forward to hearing more success stories, just as the patient told the audience in his sharing - that we should never lose hope fighting the battle against cancer!
